MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

Triple-negative breast cancers with elevated MYC are sensitized to CDK inhibition.

[1]  M. Klymkowsky,et al.  Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. , 2009, The American journal of pathology.

[2]  K. A. Gelmon.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[3]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[4]  Tobias Schmelzle,et al.  Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis , 2007, Proceedings of the National Academy of Sciences.

[5]  M. Huang,et al.  A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. , 2006, Experimental hematology.

[6]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Geerts,et al.  Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells , 2009, Proceedings of the National Academy of Sciences.

[8]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[9]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[10]  P. Yaswen,et al.  Accumulation and altered localization of telomere-associated protein TRF2 in immortally transformed and tumor-derived human breast cells , 2005, Oncogene.

[11]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[12]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[13]  Genee Y. Lee,et al.  Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.

[14]  G. Evan,et al.  Modelling Myc inhibition as a cancer therapy , 2008, Nature.

[15]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[16]  K. Shokat,et al.  Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates , 2008, Proceedings of the National Academy of Sciences.

[17]  Sarah A. Pendergrass,et al.  A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response , 2009, PloS one.

[18]  E. Lees,et al.  Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.

[19]  Eran Segal,et al.  Module map of stem cell genes guides creation of epithelial cancer stem cells. , 2008, Cell stem cell.

[20]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[21]  R. Eisenman,et al.  The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.

[22]  W. Gerald,et al.  Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer , 2009, Clinical Cancer Research.

[23]  Laurent Bélec,et al.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.

[24]  G. Schwartz,et al.  Development of cell-cycle inhibitors for cancer therapy , 2009, Current oncology.

[25]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[26]  Norhanom Abdul Wahab,et al.  Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. , 2002, International journal of molecular medicine.

[27]  Marc Nasoff,et al.  Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. , 2004, Cancer cell.

[28]  Xuming He,et al.  Non-parametric quantification of protein lysate arrays , 2007, Bioinform..

[29]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[30]  M. Cole,et al.  Mechanism of transcriptional activation by the Myc oncoproteins. , 2006, Seminars in cancer biology.

[31]  R. Eisenman,et al.  Myc's broad reach. , 2008, Genes & development.

[32]  Joe W. Gray,et al.  Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Bouillet,et al.  Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Chi V. Dang,et al.  c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.

[35]  M. Cole,et al.  The c-Myc Transactivation Domain Is a Direct Modulator of Apoptotic versus Proliferative Signals , 2000, Molecular and Cellular Biology.

[36]  R. Flavell,et al.  Multisite phosphorylation regulates Bim stability and apoptotic activity. , 2008, Molecular cell.

[37]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[38]  Jun Luo,et al.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.

[39]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  W. Hahn,et al.  The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[43]  Yun‐Sil Lee,et al.  Cdk5-mediated Phosphorylation of c-Myc on Ser-62 Is Essential in Transcriptional Activation of Cyclin B1 by Cyclin G1*S⃞ , 2008, Journal of Biological Chemistry.

[44]  S. Rodig,et al.  Altered Subcellular Localization of c-Myc Protein Identifies Aggressive B-cell Lymphomas Harboring a c-MYC Translocation , 2010, The American journal of surgical pathology.

[45]  Daniel Birnbaum,et al.  How basal are triple‐negative breast cancers? , 2008, International journal of cancer.

[46]  X. Castellsagué,et al.  Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas , 1999, Breast Cancer Research and Treatment.

[47]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[48]  Mina J. Bissell,et al.  Prognostic Breast Cancer Signature Identified from 3D Culture Model Accurately Predicts Clinical Outcome across Independent Datasets , 2008, PloS one.

[49]  M. Bissell,et al.  Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. , 2006, Cancer research.

[50]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Tward,et al.  Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC , 2007, Nature Medicine.

[52]  Daniel Jones.  Adaptive trials receive boost , 2010, Nature Reviews Drug Discovery.

[53]  David J. Nott,et al.  Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup , 2009, PloS one.

[54]  Gordon B. Mills,et al.  The energy sensing LKB1–AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis , 2007, Nature Cell Biology.

[55]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[56]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[57]  M. Yaffe,et al.  Exploiting synthetic lethal interactions for targeted cancer therapy , 2009, Cell cycle.

[58]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[59]  Hong Liu,et al.  Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase , 2010, Proceedings of the National Academy of Sciences.

[60]  Charles M. Perou,et al.  Triple-Negative Breast Cancer: Risk Factors to Potential Targets , 2008, Clinical Cancer Research.

[61]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[62]  S. Lowe,et al.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants , 2005, Nature.

[63]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[64]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[65]  Yiling Lu,et al.  Pharmacodynamic Markers of Perifosine Efficacy , 2007, Clinical Cancer Research.

[66]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[67]  Wen-Lin Kuo,et al.  Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer , 2007, Clinical Cancer Research.

[68]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[69]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[70]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[72]  Sophie Lelièvre,et al.  beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. , 2002, Cancer cell.

[73]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[74]  A. Strasser,et al.  Bim: a novel member of the Bcl‐2 family that promotes apoptosis , 1998, The EMBO journal.

[75]  James R Bischoff,et al.  CDK inhibitors in cancer therapy: what is next? , 2008, Trends in pharmacological sciences.

[76]  Nola Hylton,et al.  Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[78]  A. Letai,et al.  Mimicking the BH3 domain to kill cancer cells , 2008, Oncogene.

[79]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[80]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[81]  P. Greengard,et al.  Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[82]  K. Bland,et al.  Oncogene Protein Co‐Expression Value of Ha-ras, c-myc, c-fos, and p53 as Prognostic Discriminants for Breast Carcinoma , 1995, Annals of surgery.